Previous Article | Next Article 
J Virol, July 1998, p. 5399-5407, Vol. 72, No. 7
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Identification of Replication-Competent Strains of
Simian Immunodeficiency Virus Lacking Multiple Attachment Sites for
N-Linked Carbohydrates in Variable Regions 1 and 2 of the
Surface Envelope Protein
Julie N.
Reitter and
Ronald C.
Desrosiers*
New England Regional Primate Research Center,
Harvard Medical School, Southborough, Massachusetts 01772-9102
Received 22 October 1997/Accepted 21 March 1998
 |
ABSTRACT |
Carbohydrates comprise about 50% of the mass of gp120, the
external envelope glycoprotein of simian immunodeficiency virus (SIV)
and human immunodeficiency virus. We identified 11 replication-competent derivatives of SIVmac239 lacking two, three,
four, or five potential sites for N-linked glycosylation. These sites
were located within and around variable regions 1 and 2 of the surface
envelope protein of the virus. Asn (AAT) of the canonical N-linked
glycosylation recognition sequence (Asn X Ser/Thr) was changed in each
case to the structurally similar Gln (CAG or CAA) such that two
nucleotide changes in the codon would be required for reversion.
Replication of one triple mutant (g456), however, was severely
impaired. A revertant of the g456 mutant was recovered from CEMx174
cells with a Met-to-Val compensatory substitution at position 144, 2 amino acids upstream of attachment site 5. Thus, a debilitating loss of
sites for N-linked glycosylation can be compensated for by amino acid
changes not involving the Asn-X-Ser/Thr consensus motif. These results
provide a framework to begin testing the hypothesis that carbohydrates
form a barrier that can limit the humoral immune responses to the
virus.
 |
INTRODUCTION |
Carbohydrates comprise about 50% of
the mass of gp120, the external envelope glycoprotein of the simian and
human immunodeficiency viruses (SIV and HIV). Both N-linked and
O-linked forms of glycosylation have been detected (5, 8,
18). While the consensus sequence for the addition of N-linked
oligosaccharides is known (Asn-X-Ser/Thr), the determinants of O-linked
glycosylation are less well understood (28). The number of
N-linked sites on gp120 varies with the strain of SIV and HIV but is
usually around 24, and the locations are generally conserved within
each group (24). The detailed structural analysis by Leonard
et al. demonstrated that all 24 N-linked sites are utilized in the
gp120 of the HIV-1 IIIB strain produced in Chinese hamster ovary cells
(18).
When the envelope precursor of gp120 is produced in mammalian cells in
the presence of agents that inhibit early steps in N-linked
oligosaccharide biosynthesis, there is a marked decrease in both viral
infectivity and syncytium formation (13, 14, 27, 30).
Inhibition of mannose trimming and later steps in the processing of
N-glycans do not significantly interfere with infectivity and cell
fusion (14, 27). Deficits imparted by complete lack of
glycosylation, e.g., when synthesis occurs in the presence of
tunicamycin, include lack of proper folding, retention in the Golgi
complex, lack of proteolytic processing, and inability to bind to CD4
(10, 20). When fully glycosylated gp120 is deglycosylated
enzymatically in the absence of detergents, gp120 apparently retains
its native structure and can bind CD4 (11, 20). Thus,
carbohydrates appear to be required to generate a properly folded,
properly processed protein, but once formed the carbohydrates do not
appear to be required to maintain the native structure. Despite this
general requirement for carbohydrates, many individual N-linked sites
can be eliminated without impairing the native structure or the ability
of the virus to replicate (6, 17). However, other N-linked
sites are essential for the virus (22, 32).
Since the extensive glycosylation of HIV and SIV envelope proteins was
initially recognized, it has been speculated that the carbohydrates may
form a barrier that can limit the humoral immune response and protect
the virus from immune recognition. However, little evidence has been
presented in actual support of this hypothesis. In one study, the
reactivity of some monoclonal antibodies was increased and the
reactivity of others was decreased when gp120 was synthesized in the
presence of an oligosaccharide-processing inhibitor (12).
The authors concluded that peripheral structures of N-glycans are
involved in modulating the overall conformation of gp120
(12). In another study, the neutralizing potential of some
monoclonal antibodies was enhanced slightly when strains of virus
lacking an N-linked glycosylation site in V3 were used (4).
We are interested in using the SIV monkey model to provide a more
rigorous investigation of the hypothesis.
In this report, we describe the extent to which N-linked glycosylation
sites within and around the V1 and V2 regions of gp120 of SIVmac239 are
dispensable for viral replication.
 |
MATERIALS AND METHODS |
Site-specific mutagenesis and subcloning.
To reduce the size
of the plasmids to be mutated, a SphI-ClaI
fragment of the proviral SIVmac239 DNA containing 1469 nucleotides of
env coding sequence (proviral nucleotides 6450 to 8073 in
the numbering of Regier and Desrosiers [29]) was
subcloned into pSP72 (Promega), resulting in pSP72SC. The
SacI-EcoRI fragment containing the 3' 1,050 bases
of the proviral genome was subcloned into pSP72 to create pSP72SE.
Mutations of env were created by recombinant PCR mutagenesis
(9). Carbohydrates were numbered according to their order of
appearance within the envelope sequence of SIVmac239. The
following mutagenic primers were used: for g4, (6931 to 6970)
5'-ACTATGAGATGCCAGAAAAGTGAGACAGATAGATGGGGAT-3' and
(6957 to 6919) 5'-TGTCTCACTTTTCTGGCATCTCATAGTAATGCATAATGG-3'; for g5, (7027 to 7068)
5'-GTAGACATGGTCCAGGAGACTAGTTCTTGTATAGCCCAGGAT-3' and (7053 to 7014) 5'-AGAACTAGTCTCCTGGACCATGTCTACTTTTGCTGATGCT-3'; for
g6, (7057 to 7097) 5'-ATAGCCCAGGATCAATGCACAGGCTTGGAACAAGAGCAAAT-3' and (7084 to 7045)
5'-CCAAGCCTGTGCATTGATCCTGGGCTATACAAGAACTAGT-3'; for M144V,
(7026 to 7062) 5'-AGTAGACGTGGTCAATGAGACTAGTTCTTGTATAGCC-3' and (7045 to 7010)
5'-GTCTCATTGACCACGTCTACTTTTGCTGATGCTGTCG-3'; for g456
(M144V), (7022 to 7055) 5'-CAAAAGTAGACGTGGTCCAGGAGACTAGTTCTTG-3' and (7042 to 7009) 5'-CCTGGACCACGTCTACTTTTGCTGATGCTGTCGT-3';
for g7, (7103 to 7137)
5'-GCTGTAAATTCCAGATGACAGGGTTAAAAAGAGAC-3' and (7126 to
7092) 5'-ACCCTGTCATCTGGAATTTACAGCTTATCATTTGC-3'; for g8,
(7145 to 7180) 5'-AAGAGTACCAGGAAACTTGGTACTCTGCAGATTTGG-3' and (7164 to 7130)
5'-CCAAGTTTCCTGGTACTCTTTTTTCTTGTCTCTTTT-3'; for g9, (7186 to
7220) 5'-GAACAAGGGCAGAACACTGGTAATGAAAGTAGATG-3' and (7206 to
7171) 5'-ACCAGTGTTCTGCCCTTGTTCACATACCAAATCTGC-3'; for g10,
(7198 to 7231) 5'-AACACTGGTCAGGAAAGTAGATGTTACATGAACC-3' and
(7218 to 7184) 5'-TCTACTTTCCTGACCAGTGTTATTCCCTTGTTCAC-3'; for g11, (7228 to 7264)
5'-ACCACTGTCAGACTTCTGTTATCCAAGAGTCTTGTG-3' and (7249 to
7213) 5'-TAACAGAAGTCTGACAGTGGTTCATGTAACATCTACT-3'; and
for g12 and g13, (7228 to 7364)
5'-GATGTCAGGACACACAATATTCAGGCTTTATGCCTAA-3' and (7349 to
7313) 5'-GAATATTGTGTGTCCTGACATCTAAGCAAAGCATAAC-3'. The
primers were synthesized on a Cyclone DNA synthesizer (Biosearch, Inc.)
or purchased from Genosys Biotechnologies, Inc. (Woodlands, Texas). The
SphI-ClaI fragment containing the mutated
env sequence was excised and subcloned into the 3' parental
clone, pSP72-239-3' (15). For transient gene expression, the
wild-type envelope sequence was subcloned into the unique
XhoI and BamHI sites of the expression vector
pSVL (Pharmacia) after creation of a BamHI site 3' of the
env coding sequence by using the mutagenic primers 27 (9268 to 9302) 5'-GTATATGAAGGATCCATGGAGAAACCCAGCTGAAG-3' and 28 (9286 to 9253) 5'-CCATGGATCCTTCATATACTGTCCCTGATTGTAT-3'. The mutant envelope sequences were subcloned into the resultant pSVLenv via
the unique XhoI and ClaI sites.
DNA transfection of cultured cells.
For viral stocks, the 5'
and 3' clones of SIVmac239 were digested with SphI and
heated to 65°C for 15 min. Each right-half clone was ligated with the
left-half clone p239SpSp5' by using T4 DNA ligase. A 3-µg portion of
the ligated DNA was used to transfect CEMx174 cells treated with
DEAE-dextran (25). The vector pSVL, which expresses the
simian virus 40 late promoter, was used for transient transfection of
the wild-type and mutant env genes. A 1-µg portion of DNA
was combined with DEAE-dextran, and transfection of COS-1 cells at 80%
confluence in 35-mm diameter plates (Falcon Primaria) was performed by
the procedure of Levesque et al. (19).
Virus stocks and cell culture.
Rhesus monkey peripheral
blood mononuclear cells (PBMC), CEMx174, 221, and COS-1 cells were
maintained as described previously (21, 23). For virus
stocks, CEMx174 cells were transfected as described above. The medium
was changed every 2 days, and the supernatants were harvested at or
near the peak of virus production. Cells and debris were removed by
centrifugation, and virus contained in the supernatant was aliquoted
and stored at
70°C. The concentration of p27 antigen was measured
by an antigen capture assay (Coulter Corp., Hialeah, Fla.). For virus
infections, 5 ng of p27 was used to infect 2.5 million pelleted cells.
DNA sequencing and PCR amplification.
Cloned fragments
containing mutated envelope DNA were sequenced in their entirety on an
ABI377 automated DNA sequencer by using dye terminator cycle-sequencing
chemistry as specified by the manufacturer (Perkin-Elmer Inc., Foster
City, Calif.). Total genomic DNA was isolated with the AmpPrep kit (HRI
Research, Inc., Concord, Calif.) and used as a template for nested PCR
amplification with primers located outside of the viral
env sequence. The outer primers were 39 (6320 to 6348)
5'-GAGGGAGCAGGAGAACTCATTAGAATCCTCC-3' and 40 (9373 to
9405) 5'-GTTCTTAGGGGAACTTTTGGCCTCACTGATACC-3'. The inner
mutagenic primers created XhoI and BamHI sites
used for cloning the PCR products into pSP72 and were 38 (6423 to 6465) 5'-CTCAGCTATACCGCCCTCGAGAAGCATGCTATAAC-3' and 32 (9256 to
9288) 5'-CTCCATGGATCCTTCATATACTGTCCCTGATTG-3'. Each 100-µl
reaction mix contained 1 µg of total DNA, 2 mM Mg2+, 200 µM each deoxynucleoside triphosphate, 0.2 µM each primer, and 2 U
of Vent polymerase (New England Biolabs, Beverly, Mass.), and the
mixtures were amplified for 30 cycles. Each cycle consisted of
denaturation at 93°C for 1 min, annealing at 50°C for 1 min, and
elongation at 72°C for 3 min 15 s, ending with a 10-min final extension at 72°C.
Immunoblotting and CD4 binding.
For Western analysis,
transfected COS-1 cells were rinsed three times with phosphate-buffered
saline (PBS) and lysed in 0.5 ml of lysis buffer (1% Triton X-100,
0.5% sodium deoxycholate, 10 mM NaCl, 1.5 mM MgCl2, 10 mM
Tris-HCl [pH 7.4], 5 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 1 mM Pefabloc, 1 mg of iodoacetamide). A 20-µl volume of extract was
mixed with an equal amount of sample buffer and boiled for 4 min.
Following electrophoresis, the proteins were transferred to a
polyvinylidene difluoride membrane (Millipore) and incubated
sequentially with a rhesus polyclonal antibody generated against
SIVmac239 followed by horseradish peroxidase-conjugated anti-rhesus
immunoglobulin G (Southern Biotechnology Associates). The membranes
were reacted with a chemiluminescent substrate (ECL reagents; Amersham)
and placed against film (Kodak BioMax) for 5 to 200 s. For
metabolic labeling, COS-1 cells were transfected and then cultured for
3 days. The cells were starved for 30 min by replacing the culture
medium with labeling medium (minimum essential medium without
methionine or cysteine but with 10% dialyzed fetal calf serum). The
cold medium was replaced with 1 ml of the same medium containing 100 µCi of [35S]methionine and [35S]cysteine
(Dupont NEN, Boston, Mass.), and the cells were returned to culture at
37°C. The length of the labeling period varied depending on the assay
and is indicated in the figure legends. At the end of the labeling
period, the cells were washed twice in PBS and lysed in 0.5 ml of lysis
buffer. All the lysates were frozen at
20°C, thawed, and vortexed
vigorously, and the cell debris was pelleted by centrifugation for 5 min. For CD4 binding assays, 100 µl of each lysate was incubated with
either PBS or 250 ng of soluble CD4 as described previously
(23). For the shedding assay (see Fig. 9), the transfected
cells were cultured for 3 days. The culture medium was replaced with
labeling medium, and the cells were metabolically labeled for 44 h. The assay was repeated twice with shorter labeling times of 18 and
30 h and gave similar results. For immunoprecipitations, after the
labeling period, supernatants were clarified by centrifugation for 5 min and the labeled proteins in the supernatants or 100 µl of lysates
were immunoprecipitated with serum obtained from a rhesus macaque
infected with SIVmac239. For the pulse-chase experiment (see Fig. 10),
the entire extract was immunoprecipitated. The immune complexes were precipitated with protein A-agarose (Santa Cruz), washed, and resolved
on a 10% polyacrylamide-sodium dodecyl sulfate (SDS) gel.
N-Glycosidase F digestions.
Immunoprecipitated
proteins were denatured by boiling for 2 min in 20 µl of 0.1%
SDS-1% 2-mercaptoethanol-20 mM sodium phosphate buffer (pH 8). The
sample volume was brought up to 80 µl in 1% Triton-20 mM sodium
phosphate buffer-10 mM EDTA. The samples were split into aliquots, and
either 2 U of N-glycosidase F (Boehringer) in a volume of 10 µl was added or, for mock digestions, 10 µl of sodium phosphate
buffer was added. The samples were incubated at 37°C for 20 h,
dried, and resuspended in 30 µl of sample buffer containing 5%
2-mercaptoethanol.
 |
RESULTS |
Replication of mutant viruses involving fourth, fifth, and sixth
sites.
The fourth, fifth, and sixth sites containing Asn-X-Ser/Thr
in the gp120 sequence of SIVmac239 were initially selected for mutagenesis (Fig. 1). These sites are
located in the vicinity of the highly variable region 1 but nonetheless
are strongly conserved among SIV sequences in the database
(24). The Asn codon at all three sites of SIVmac239 is AAT.
The AAT codon at sites 4 and 5 was changed to CAG (Gln), and at site 6 it was changed to CAA (Gln). Glutamine is structurally similar to
asparagine, differing only by a single CH2 group. Since
only AAT and AAC can code for Asn, two nucleotide changes would be
required for the codon to revert to an Asn codon. All seven possible
mutant forms of these sites were created. These are referred to as g4,
g5, g6, g45, g46, g56, and g456.

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 1.
(A) Linear depiction of the SIVmac239 envelope gp120
subunit showing the approximate location of potential sites for
N-linked oligosaccharides ( ) in relation to the five regions
exhibiting variability in amino acid sequence (shaded boxes labeled V1
to V5) and signal sequence (V0). (B) Wild-type and mutant amino acid
sequences. Amino acids 114 to 158 of the V1 and adjacent regions are
shown. The fourth, fifth, and sixth potential glycosylation sites are
underlined. The amino acid substitutions made in the viral genome are
shown. The N-to-Q substitution removes the potential for the addition
of N-linked carbohydrate. The mutation nomenclature is shown on the
left. The M144V compensatory mutation is also shown.
|
|
All six single and double mutants (g4, g5, g6, g45, g46, and g56)
replicated similarly to the parental virus upon transfection
of cloned
DNA into CEMx174 cells (data not shown). Normalized
amounts of mutant
and parental virus stocks produced from CEMx174
transfection were used
to analyze viral replication in CEMx174
cells, the rhesus monkey 221 cell line, and primary rhesus monkey
PBMC cultures. Again, all single-
and double-mutant forms of the
virus replicated similarly to the
parental virus in CEMx174 cells
(Fig.
2A
and B), 221 cells (data not shown), and stimulated rhesus
monkey PBMC
cultures (Fig.
2C). Slight delays or differences in
peak heights were
observed with the mutants in some experiments,
but it is uncertain
whether these represent a significant difference.

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 2.
Replication of cloned SIVmac239 and env
variants generated by site-directed mutagenesis in CEMx174 cells (A and
B) and rhesus PBMC (C). Virus containing 5 ng of p27 was used for all
infections. Virus production was monitored by an assay of p27 antigen
at the indicated number of days postinfection.
|
|
Utilization of sites.
Utilization of the fourth, fifth, and
sixth potential sites was investigated by examining the mobility of the
proteins in SDS-polyacrylamide gels. Vectors for transient expression
of the wild-type and all mutant env sequences were
constructed and transfected into COS-1 cells. Only slight size
differences were apparent when the gp160 molecules of the panel of
labeled envelope proteins were immunoprecipitated and resolved by gel
electrophoresis (Fig. 3A, lanes 10 to
18). When N-glycans were removed by treatment with
N-glycosidase F, all precursor molecules comigrated, as
expected, at approximately 110 kDa, indicating that any size
differences between the envelope proteins were due entirely to
differences in N-linked glycosylation (lanes 1 to 9). To enhance the
detection of size differences among the mutant envelope proteins, a
smaller fragment of the envelope protein was generated by acid
hydrolysis. Labeled proteins were immunoprecipitated from transfected
COS-1 cells and treated with dilute acetic acid. This treatment
hydrolyzes proteins between the aspartic acid and proline residues at
positions 385 and 740 of the SIV gp160, resulting in fragments of 385, 355, and 140 residues. The first 385 amino acids of gp160 contain 20 signals for N-linked carbohydrates, and each glycan adds approximately 2,500 Da to the relative mass of the fragment (16). Thus,
this 385-aa fragment of the wild-type protein is predicted to migrate at approximately 91 kDa. Protein fragments representing these amino-terminal 385 residues of the wild-type and mutant envelope proteins are shown in Fig. 3B. The three single mutants showed an
increase in mobility of approximately 3 kDa with respect to the
wild-type protein which migrated, as expected, between 90 and 92 kDa
(Fig. 3B, lanes 2 to 5). The double mutants showed an additional
increase in mobility (lanes 6 to 8), while the triple mutant, g456, had
a further increase in mobility (lane 9). These results are consistent
with utilization of each of the fourth, fifth, and sixth N-linked
glycosylation sites.

View larger version (25K):
[in this window]
[in a new window]

View larger version (51K):
[in this window]
[in a new window]
|
FIG. 3.
Utilization of sites. COS-1 cells were transfected with
pSVL plasmid containing wild-type (wt) or mutant env DNA.
(A) On day 3 posttransfection, the cells were radioactively labeled for
5.5 h. Proteins present in the cell extracts were
immunoprecipitated with rhesus anti-SIV polyclonal sera and digested
(lanes 1 to 9) or mock digested (lanes 10 to 18) with
N-glycosidase F. Lanes: 1 and 10, vector DNA; 2 and 11, wild
type; 3 and 12 g4; 4 and 13, g5; 5 and 14, g6; 6 and 15, g45; 7 and 16, g46; 8 and 17, g56; 9 and 18, g456. (B) On day 3 posttransfection, the
cells were radioactively labeled for 19 h. Proteins present in the
cell extracts were immunoprecipitated, and the pelleted material was
hydrolyzed in 10% glacial acetic acid for 66 h at 40°C. The
hydrolyzed samples were dried before being dissolved in sample buffer
and boiled for 3 min. Lanes: 1, parental vector DNA; 2, wild type; 3, g4; 4, g5; 5, g6; 6, g45; 7, g46; 8, g56; 9, g456. Numbers on the left
indicate the relative positions of molecular mass markers and are shown
in kilodaltons. Lanes 1 to 9 in panel B are in the same order as lanes
1 to 9 in panel A.
|
|
Identification of a revertant of the triple mutant.
In
contrast to the results with the single and double mutants, replication
of the triple mutant (g456) was undetectable after transfection of
CEMx174 and 221 cells (data not shown). In one CEMx174 culture
transfected with g456 viral DNA, detectable virus began to appear
beyond 40 days after transfection (Fig.
4A). When virus from day 63 of this
transfection was used to infect CEMx174 cells, the virus replicated
with only a slight delay compared to the parental virus (Fig. 4B).
These findings suggested that reversions or compensatory changes had
appeared in the culture to allow wild-type or near-wild-type levels of
viral replication.

View larger version (12K):
[in this window]
[in a new window]
|
FIG. 4.
(A) Growth kinetics of wild-type (WT) virus and mutant
virus g456 following transfection of CEMx174 cells. (B) Growth kinetics
in CEMx174 cells of 5 ng of p27 of wild-type and uncloned revertant
virus stock obtained from culture shown in panel A on day 63 posttransfection.
|
|
Sequence analysis of viral DNA derived from CEMx174 cells infected with
the g456 revertant revealed a single predominant change
of Met to Val
at position 144 (Fig.
5). This position
is located
2 amino acids upstream of the mutated fifth N-linked site.
No
changes were observed in the fourth, fifth, and sixth QXS/T sites
themselves (Fig.
5). We introduced the Val-to-Met change into
the
parental SIV239 DNA and into the g456 mutant in the absence
of any
other changes. Virus containing the M144V change in the
239 background
replicated similarly to the parental SIVmac239
upon transfection (data
not shown) and infection of both the CEMx174
and 221 cell lines (Fig.
6A and B). Virus containing the M144V
change in the g456 background replicated with only a slight delay
compared to SIVmac239 upon both transfection (data not shown)
and
infection of both CEMx174 and 221 cells (Fig.
6A and B). The
virus with
the M144V mutation in the g456 background replicated
with kinetics
similar to that of the revertant recovered from
the original
transfection (Fig.
4B). Thus, the change of Met to
Val at position 144 is able to compensate for the loss of the
fourth, fifth, and
sixth NXS/T sites. However, replication of
the g456MV variant was
severely impaired after infection of stimulated
rhesus monkey PBMC
(Fig.
6C).

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 5.
Amino acid sequences deduced from env clones
obtained from CEMx174 cells infected with the g456rev virus stock for
14 days. Genomic DNA was recovered, and five clones were obtained by
PCR. Both strands of the amino-terminal 1,350 bases of each clone were
sequenced. The first 450 residues of the parental g456 envelope
sequence are shown. The three asparagine-to-glutamine substitutions are
shown in boldface type. Sites g4, g5, and g6 are underlined. Dots
represent identity. Lowercase letters indicate silent mutations.
Capital letters indicate amino acid substitutions.
|
|

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 6.
Replication of wild-type SIVmac239 and M144V mutants
following infection of CEMx174 cells (A), 221 cells (B), and rhesus
PBMC (C). Virus containing 5 ng of p27 was used for all infections.
Virus production was monitored by an assay of p27 antigen at the
indicated number of days postinfection.
|
|
Nature of the block to replication.
We performed experiments
to evaluate both the nature of the block to replication with the g456
mutant and the way in which the M-to-V substitution may relieve this
block. Vectors for transient expression of wild-type, g456, and g456MV
envelope proteins were transfected into COS-1 cells. Envelope
protein expression, processing, and size were evaluated by
Western blot analysis of cell extracts on days 2, 3, 4, and 5 after
transfection (Fig. 7). The parental clone
yielded both the gp160 precursor and the proteolytically processed
gp120 external surface subunit as expected during the 2- to 5-day
period that was examined (Fig. 7). Both the g456 and g456MV mutants
yielded a precursor that migrated faster than the gp160 precursor of
the parental virus (Fig. 7). Less processed "gp120" was observed in
cells expressing the g456 mutant than in cells expressing the
parental envelope, while g456MV expressed intermediate
levels (Fig. 7).

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 7.
Proteolytic processing of wild-type and mutant envelope
protein expressed in COS-1 cells. COS-1 cells were transfected with
pSVL vector expressing wild-type or mutant envelope sequence. Cell
lysates were obtained on the days indicated and electrophoresed in an
8% polyacrylamide-SDS gel, transferred to a membrane, and reacted
with a polyclonal serum obtained from a rhesus monkey infected with
SIVmac239. V, parental plasmid; WT, SIVmac239 env; g456 and g456MV
env substitutions are depicted in Fig. 1.
|
|
We next assessed the ability of the g456 envelope protein to bind CD4
receptor by measuring binding to sCD4. Transfected COS-1
cells were
cultured for 3 days and then labeled with
[
35S] methionine and [
35S]cysteine for
24 h. Labeled envelope protein in the cell lysate
was tested for
its ability to bind to soluble CD4. CD4-env protein
complexes
were immunoprecipitated with the OKT4 anti-CD4 monoclonal
antibody, whose reactivity is not blocked by the CD4-env
interaction.
Under the conditions used for this assay, both mutant
envelope
proteins were able to bind to the soluble CD4 (Fig.
8). We have
shown previously that the
gp160 precursor of SIVmac239 is capable
of binding to soluble CD4
(
23).

View larger version (42K):
[in this window]
[in a new window]
|
FIG. 8.
CD4 binding ability of mutant envelope proteins.
Transfected COS-1 cells expressing wild-type or mutant envelope
proteins were labeled for 24 h with [35S]cysteine
and [35S]methionine as described in Materials and
Methods. Proteins in the labeled cell extracts were immunoprecipitated
with polyclonal antiserum to SIVmac239 (lanes 1, 4, 7, and 10). Labeled
cell extracts were incubated with soluble CD4, and the
env-CD4 complexes were immunoprecipitated with anti-CD4 MAb
OKT4 (lanes 3, 6, 9, and 12). Antigen-antibody complexes were
precipitated with protein A/protein G-agarose and analyzed by
electrophoresis in a 10% polyacrylamide-SDS gel. Lanes: 1 to 3, vector (v); 4 to 6, wild-type (WT) envelope; 7 to 9, g456 envelope; 10 to 12, g456MV envelope.
|
|
Since only a small amount of g456 gp120 equivalent was detected in
cells both by Western blot analysis and immunoprecipitation,
loss of
"gp120" by release into the medium was evaluated by labeling
transfected COS-1 cells with [
35S]methionine and
[
35S]cysteine and immunoprecipitating "gp120" from
the cell-free
supernatants. "gp120" was detected in the supernatant
in all cases
(Fig.
9). Upon two
repetitions of the assay, the g456 virus consistently
released higher
levels of gp120 than did the wild-type. Processing
of "gp160"
precursor and loss of "gp120" by release into the medium
was also
evaluated by a pulse-chase experiment (Fig.
10). The results
of these assays were
consistent with those of the other methods,
suggesting that there were
decreased amounts of processed "gp120"
of g456 in cells and
increased amounts of "gp120" released into
the media.

View larger version (42K):
[in this window]
[in a new window]
|
FIG. 9.
gp120 shedding. Transfected COS-1 cells expressing
wild-type (WT) or mutant envelope proteins were labeled for 44 h
at 3 days posttransfection. Proteins in the supernatant were
immunoprecipitated with polyclonal antiserum to SIVmac239. Similar
results were obtained after repetitions of the assay with labeling
periods of 18 and 30 h.
|
|

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 10.
Pulse-chase analysis. COS-1 cells were transfected in
quadruplicate and cultured for 3 days. All the cultures were
pulse-labeled for 4 h. The labeling medium was replaced with cold
medium, and samples were harvested at the end of the pulse and at chase
times of 4, 8, and 20 h as indicated above the lanes. At the end
of the pulse or the chase periods, the supernatants were collected and
labeled envelope proteins within the cell extract or supernatants were
immunoprecipitated as described previously. Cell extracts, lanes 1 to
4, 9 to 12, and 17 to 20; supernatants, lanes 5 to 8, 13 to 16, and 21 to 24. P, pulse label, lanes 1, 5, 9, 13, 17, and 21.
|
|
Replication of additional mutants.
To examine the importance
for replication of other sites for N-linked carbohydrates around the V1
and V2 regions, additional asparagine codons were replaced with the
codon for glutamine. Mutants were created that lacked various
combinations of the 4th through 13th glycosylation sites. Alteration of
the 8th or 10th site or both the 12th and 13th sites for N-linked
glycosylation had no effect on viral replication in CEMx174 cells (data
not shown). Viral replication was not significantly affected when three
consecutive or nonconsecutive potential glycosylation sites were
altered (Fig. 11A and C). Furthermore,
multiple combinations of env mutants lacking four or five
glycosylation sites were also replication competent in CEMx174 cells
(Fig. 11B) as well as 221 cells (not shown) and stimulated rhesus PBMCs
(Fig. 11D). Thus, elimination of multiple combinations of carbohydrate
attachment sites between g4 and g13 yielded virus that was still
replication competent.

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 11.
Replication of SIV variants lacking additional N-linked
carbohydrate attachment sites. Virus containing 5 ng of p27 was used to
infect PBMCs or CEMx174 cells as described in the legend to Fig. 2. The
nomenclature indicates the position of the asparagine residues in the
potential glycosylation sites that were substituted with a glutamine.
(A and B) Replication in CEMx174 cells. (C and D) Replication in
stimulated rhesus PBMCs.
|
|
 |
DISCUSSION |
V1 has been described as being the most variable of the
hypervariable regions of the external subunit of SIVmac (3,
7). In spite of this variation, potential sites for carbohydrate
addition are present near the boundaries of the V1 region in most
isolates of SIV and HIV-2 listed in the Los Alamos database
(24). This conservation suggests that selective pressure is
working to maintain the presence of these V1 carbohydrate attachment
sites. In addition, the positions of the fourth and fifth carbohydrate
sites are absolutely conserved for all SIVs (24). The
positioning of the sixth N-linked glycosylation site is slightly
less conserved and sometimes shifts in position by 2 amino acids
(24). One might expect from this conservation an important
role for the g4 through g6 canonical N-linked sites for some aspect of
the viral life cycle. Our study of SIV gp120 mutants has shown that the
asparagine residues of the fourth, fifth, and sixth canonical
Asn-Xaa-Ser/Thr N-linked glycosylation sites can be replaced
individually and in all pairwise combinations with a glutamine residue
without detectably influencing the kinetics of viral replication in
cell culture.
SDS-polyacrylamide gel electrophoresis following metabolic labeling and
acid hydrolysis demonstrated increased mobility of the g4, g5, and g6
individual mutant envelope proteins. The double mutants exhibited even
further increased mobility, while the triple mutant had an additional
increase in mobility. Removal of the N-linked glycans resulted in the
comigration of all envelope species. These results are consistent with
the attachment of N-linked carbohydrates to the fourth, fifth, and
sixth canonical sites in the parental sequence.
The g456 mutant exhibited decreased levels of its gp120 equivalent
associated with cells and increased shedding of its "gp120" into
the cell-free supernatant. These results suggest that the g456 mutant
is deficient in the association of its "gp120" with the gp41
transmembrane subunit. The growth defect of the g456 virus may thus be
due in part to the decrease in association of the g456 surface protein
with the gp41 transmembrane protein. Consistent with this, the g456MV
variant exhibited increased association of its "gp120" with the
cell and decreased shedding into the cell-free supernatant. However,
the severe growth defect of the g456 mutant cannot be easily explained
by the somewhat subtle differences in processing and gp41 association
that were observed. Underglycosylated viral glycoproteins have
previously been shown to have impaired assembly (26), and it
is possible that the g456 env molecule is deficient in its
oligomerization, since this would not necessarily have been detected by
the methods used. Differences in the affinity of association with
primary or secondary receptors are also possible.
The g456MV variant replicated well in the rhesus monkey cell line 221 but, surprisingly, replicated poorly in stimulated rhesus monkey PBMC
cultures. The 221 cell line is immortalized by herpesvirus saimiri
(2) and could possibly express the virus-encoded
G-protein-coupled receptor which is a homolog of the interleukin-8
(IL-8) receptor (vIL-8R) (1). Thus, one possible explanation
for the differential growth of g456MV in 221 and rhesus monkey PBMC is
the use of alternate or unusual second receptors that allow entry into
CEMx174 and 221 cells but not into stimulated rhesus PBMC.
The finding that only the M144V substitution arose to compensate for
the absence of all three potential carbohydrates was surprising due to
the large number of serines and threonines within the V1 region that
could be used to regenerate new glycosylation sites. Curiously, this
methionine-to-valine substitution is found naturally in some MNE and
SMM isolates which are not derived from the SIVmac239 or SIVmac251
strains (24). We did not see any difference in viral
replication when only the M144V substitution was introduced into the
parental SIV239 genome. Our results with SIV are similar in some
respects to those described by Wang et al. for HIV-1 (31).
In that study, the authors found that simultaneously altering three of
six N-linked glycosylation sites in the V1-V2 sequence of HIV-1
HXB2 resulted in gross impairment of virus infectivity. Study of
revertants of this mutant revealed that an upstream
isoleucine-to-valine substitution conferred the revertant phenotype
(31). Similarly, Willey et al. found that the absence
of viral replication following the loss of N-linked glycosylation at
residue 276 of HIVNL4-3 could be restored with substitutions that do
not create a new glycosylation site (32).
We have identified strains simultaneously lacking as many as five of
the potential N-linked sites in gp120. This represents a loss of half
of all the N-linked glycan addition sites in the region covered by
residues 114 to 247. No one, to our knowledge, has identified
replication-competent strains of SIV or HIV that are this deficient in
glycosylation. In addition, viral replication was tolerant to removal
of a series of adjacent carbohydrate-addition sites. This was
indicated by growth of the g5678 variant. Replication of the g11, g12,
g13 virus is especially noteworthy. The g11 site is absolutely
conserved among the 54 HIV-2 and SIV isolates listed in the 1996 database, while the g12 and g13 sites are just slightly less conserved
(24). Our results indicate that none of the 10 sites for the
addition of N-linked carbohydrate in the vicinity of the V1 and V2
regions is individually required for viral replication. The mutants
described in this report will allow us to begin investigating the
effects of loss of N-linked carbohydrate attachment sites in the V1 and
V2 regions on the nature and quality of the humoral immune response.
 |
ACKNOWLEDGMENTS |
We thank Dean Regier for assistance with DNA sequencing and
Joanne Newton for preparation of the manuscript.
This work was supported by Public Health Service grants AI35365 and
RR00168.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: New England
Regional Primate Research Center, Harvard Medical School, One Pine Hill Dr., Box 9102, Southborough, MA 01772-9102. Phone: (508) 624-8042. Fax:
(508) 624-8190. E-mail:
rdesrosi{at}warren.med.harvard.edu.
 |
REFERENCES |
| 1.
|
Ahuja, S. K., and P. M. Murphy.
1996.
Molecular piracy of mammalian interleukin-8 receptor type B by herpesvirus saimiri.
J. Biol. Chem.
268:20691-20694[Abstract/Free Full Text].
|
| 2.
|
Alexander, L.,
Z. Du,
M. Rosenzweig,
J. U. Jung, and R. C. Desrosiers.
1997.
A role for natural simian immunodeficiency virus and human immunodeficiency virus type 1 nef alleles in lymphocyte activation.
J. Virol.
71:6094-6099[Abstract].
|
| 3.
|
Almond, N.,
A. Jenkins,
A. B. Heath, and P. Kitchin.
1993.
Sequence variation in the env gene of simian immunodeficiency virus recovered from immunized macaques is predominantly in the V1 region.
J. Gen. Virol.
74:865-871[Abstract/Free Full Text].
|
| 4.
|
Back, N. K. T.,
L. Smit,
J.-J. De Jong,
W. Keulen,
M. Schutten,
J. Goudsmit, and M. Tersmette.
1994.
An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization.
Virology
199:431-438[Medline].
|
| 5.
|
Bernstein, H. B.,
S. P. Tucker,
E. Hunter,
J. S. Schutzbach, and R. W. Compans.
1994.
Human immunodeficiency virus type 1 envelope glycoprotein is modified by O-linked oligosaccharides.
J. Virol.
68:463-468[Abstract/Free Full Text].
|
| 6.
|
Bolmstedt, A.,
A. Hemming,
P. Flodby,
P. Berntsson,
B. Travis,
J. P. C. Lin,
J. Ledbetter,
T. Tsu,
H. Wigzell,
S.-L. Hu, and S. Olofsson.
1991.
Effects of mutations in glycosylation sites and disulphide bonds on processing, CD4-binding and fusion activity of human immunodeficiency virus envelope glycoproteins.
J. Gen. Virol.
72:1269-1277[Abstract/Free Full Text].
|
| 7.
|
Burns, D. P. W., and R. C. Desrosiers.
1991.
Selection of genetic variants of simian immunodeficiency virus in persistently infected rhesus monkeys.
J. Virol.
65:1843-1854[Abstract/Free Full Text].
|
| 8.
|
Chackerian, B.,
L. M. Rudensey, and J. Overbaugh.
1997.
Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus that evolve in the host alter recognition by neutralizing antibodies.
J. Virol.
71:7719-7727[Abstract].
|
| 9.
|
Du, Z.,
D. A. Regier, and R. C. Desrosiers.
1995.
An improved recombinant PCR mutagenesis procedure that uses alkaline denatured plasmid template.
BioTechniques
18:376-378.
[Medline] |
| 10.
|
Fennie, C., and L. A. Lasky.
1989.
Model for intracellular folding of the human immunodeficiency virus type 1 gp120.
J. Virol.
63:639-646[Abstract/Free Full Text].
|
| 11.
|
Fenouillet, E.,
J. C. Gluckman, and E. Bahraoui.
1990.
Role of N-linked glycans of envelope glycoproteins in infectivity of human immunodeficiency virus type 1.
J. Virol.
64:2841-2848[Abstract/Free Full Text].
|
| 12.
|
Fischer, P. B.,
G. B. Karlsson,
T. D. Butters,
R. A. Dwek, and F. M. Platt.
1996.
N-Butyldeoxynojirimycin-mediated inhibition of human immunodeficiency virus entry correlates with changes in antibody recognition of the V1/V2 region of gp120.
J. Virol.
70:7143-7152[Abstract/Free Full Text].
|
| 13.
|
Fischer, P. B.,
G. B. Karlsson,
R. A. Dwek, and F. M. Platt.
1996.
N-Butyldeoxynojirimycin-mediated inhibition of human immunodeficiency virus entry correlates with impaired gp120 shedding and gp41 exposure.
J. Virol.
70:7153-7160[Abstract/Free Full Text].
|
| 14.
|
Gruters, R. A.,
J. J. Neefjes,
M. Tersmette,
R. E. Y. de Goede,
A. Tulp,
H. G. Huisman,
F. Miedema, and H. L. Ploegh.
1987.
Interference with HIV-induced syncytium formation and viral infectivity by inhibitors of trimming glucosidase.
Nature
330:74-77[Medline].
|
| 15.
|
Ilyinskii, P. O., and R. C. Desrosiers.
1996.
Efficient transcription and replication of simian immunodeficiency virus in the absence of NF- B and Sp1 binding elements.
J. Virol.
70:3118-3126[Abstract].
|
| 16.
|
Kornfeld, R., and S. Kornfeld.
1985.
Assembly of asparagine-linked oligosaccharides.
Annu. Rev. Biochem
54:631-664[Medline].
|
| 17.
|
Lee, W.-R.,
W.-J. Syu,
B. Du,
M. Matsuda,
S. Tan,
A. Wolf,
M. Essex, and T.-H. Lee.
1992.
Nonrandom distribution of gp120 N-linked glycosylation sites important for infectivity of human immunodeficiency virus type 1.
Proc. Natl. Acad. Sci. USA
89:2213-2217[Abstract/Free Full Text].
|
| 18.
|
Leonard, C. K.,
M. W. Spellman,
L. Riddle,
R. J. Harris,
J. N. Thomas, and T. J. Gregory.
1990.
Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells.
J. Biol. Chem.
265:10373-10382[Abstract/Free Full Text].
|
| 19.
|
Levesque, J.-P.,
P. Sanilvestri,
A. Hatzfeld, and J. Hatzfeld.
1991.
DNA transfection in Cos cells.
BioTechniques
11:313-318.
|
| 20.
|
Li, Y.,
L. Luo,
N. Rasool, and C. Y. Kang.
1993.
Glycosylation is necessary for the correct folding of human immunodeficiency virus gp120 in CD4 binding.
J. Virol.
67:584-588[Abstract/Free Full Text].
|
| 21.
|
Mori, K.,
D. J. Ringler,
T. Kodama, and R. C. Desrosiers.
1992.
Complex determinants of macrophage tropism in env of simian immunodeficiency virus.
J. Virol.
66:2067-2075[Abstract/Free Full Text].
|
| 22.
|
Morikawa, Y.,
J. P. Moore,
A. J. Wilkinson, and I. M. Jones.
1991.
Reduction in CD4 binding affinity associated with removal of a single glycosylation site in the external glycoprotein of HIV-2.
Virology
180:853-856[Medline].
|
| 23.
|
Morrison, H. G.,
F. Kirchhoff, and R. C. Desrosiers.
1993.
Evidence for the cooperation of gp120 amino acids 322 and 448 in SIVmac entry.
Virology
195:167-174[Medline].
|
| 24.
|
Myers, G.,
B. Foley,
J. W. Mellors,
B. Korber,
K.-T. Jeang, and S. Wain-Hobson.
1996.
In
A compilation and analysis of nucleic acid and amino acid sequences.
Los Alamos National Laboratory, Los Alamos, N.M.
|
| 25.
|
Naidu, Y. M.,
H. W. Kestler, III,
Y. Li,
C. V. Butler,
D. P. Silva,
D. K. Schmidt,
C. D. Troup,
P. K. Sehgal,
P. Sonigo,
M. D. Daniel, and R. C. Desrosiers.
1988.
Characterization of infectious molecular clones of simian immunodeficiency virus (SIVmac) and human immunodeficiency virus type 2: persistent infection of rhesus monkeys with molecularly cloned SIVmac.
J. Virol.
62:4691-4696[Abstract/Free Full Text].
|
| 26.
|
Ng, D. T. W.,
S. W. Hiebert, and R. A. Lamb.
1990.
Different roles of individual N-linked oligosaccharide chains in folding, assembly, and transport of the simian virus 5 hemagglutinin-neuraminidase.
Mol. Cell. Biol.
10:1989-2001[Abstract/Free Full Text].
|
| 27.
|
Pal, R.,
G. M. Hoke, and M. G. Sarngadharan.
1989.
Role of oligosaccharides in the processing and maturation of envelope glycoproteins of human immunodeficiency virus type 1.
Proc. Natl. Acad. Sci. USA
86:3384-3388[Abstract/Free Full Text].
|
| 28.
|
Pinter, A., and W. J. Honnen.
1988.
O-linked glycosylation of retroviral envelope gene products.
J. Virol.
62:1016-1021[Abstract/Free Full Text].
|
| 29.
|
Regier, D. A., and R. C. Desrosiers.
1990.
The complete nucleotide sequence of a pathogenic molecular clone of simian immunodeficiency virus.
AIDS Res. Hum. Retroviruses
6:1221-1231[Medline].
|
| 30.
|
Walker, B. D.,
M. Kowalski,
W. C. Goh,
K. Kozarsky,
M. Krieger,
C. Rosen,
L. Rohrschneider,
W. A. Haseltine, and J. Sodroski.
1987.
Inhibition of human immunodeficiency virus syncytium formation and virus replication by castanospermine.
Proc. Natl. Acad. Sci. USA
84:8120-8124[Abstract/Free Full Text].
|
| 31.
|
Wang, W.-K.,
M. Essex, and T.-H. Lee.
1996.
Single amino acid substitution in constant region 1 or 4 of gp120 causes the phenotype of a human immunodeficiency virus type 1 variant with mutations in hypervariable regions 1 and 2 to revert.
J. Virol.
70:607-611[Abstract].
|
| 32.
|
Willey, R. L.,
D. H. Smith,
L. A. Lasky,
T. S. Theodore,
P. L. Earl,
B. Moss,
D. J. Capon, and M. A. Martin.
1988.
In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity.
J. Virol.
62:139-147[Abstract/Free Full Text].
|
J Virol, July 1998, p. 5399-5407, Vol. 72, No. 7
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Yuste, E., Bixby, J., Lifson, J., Sato, S., Johnson, W., Desrosiers, R.
(2008). Glycosylation of gp41 of Simian Immunodeficiency Virus Shields Epitopes That Can Be Targets for Neutralizing Antibodies. J. Virol.
82: 12472-12486
[Abstract]
[Full Text]
-
Li, Y., Cleveland, B., Klots, I., Travis, B., Richardson, B. A., Anderson, D., Montefiori, D., Polacino, P., Hu, S.-L.
(2008). Removal of a Single N-Linked Glycan in Human Immunodeficiency Virus Type 1 gp120 Results in an Enhanced Ability To Induce Neutralizing Antibody Responses. J. Virol.
82: 638-651
[Abstract]
[Full Text]
-
Yuste, E., Johnson, W., Pavlakis, G. N., Desrosiers, R. C.
(2005). Virion Envelope Content, Infectivity, and Neutralization Sensitivity of Simian Immunodeficiency Virus. J. Virol.
79: 12455-12463
[Abstract]
[Full Text]
-
Pikora, C., Wittish, C., Desrosiers, R. C.
(2005). Identification of Two N-Linked Glycosylation Sites within the Core of the Simian Immunodeficiency Virus Glycoprotein Whose Removal Enhances Sensitivity to Soluble CD4. J. Virol.
79: 12575-12583
[Abstract]
[Full Text]
-
Luftenegger, D., Picard-Maureau, M., Stanke, N., Rethwilm, A., Lindemann, D.
(2005). Analysis and Function of Prototype Foamy Virus Envelope N Glycosylation. J. Virol.
79: 7664-7672
[Abstract]
[Full Text]
-
Panda, A., Elankumaran, S., Krishnamurthy, S., Huang, Z., Samal, S. K.
(2004). Loss of N-Linked Glycosylation from the Hemagglutinin- Neuraminidase Protein Alters Virulence of Newcastle Disease Virus. J. Virol.
78: 4965-4975
[Abstract]
[Full Text]
-
McCaffrey, R. A., Saunders, C., Hensel, M., Stamatatos, L.
(2004). N-Linked Glycosylation of the V3 Loop and the Immunologically Silent Face of gp120 Protects Human Immunodeficiency Virus Type 1 SF162 from Neutralization by Anti-gp120 and Anti-gp41 Antibodies. J. Virol.
78: 3279-3295
[Abstract]
[Full Text]
-
Kutok, J. L., Klumpp, S., Simon, M., MacKey, J. J., Nguyen, V., Middeldorp, J. M., Aster, J. C., Wang, F.
(2004). Molecular Evidence for Rhesus Lymphocryptovirus Infection of Epithelial Cells in Immunosuppressed Rhesus Macaques. J. Virol.
78: 3455-3461
[Abstract]
[Full Text]
-
Cole, K. S., Steckbeck, J. D., Rowles, J. L., Desrosiers, R. C., Montelaro, R. C.
(2004). Removal of N-Linked Glycosylation Sites in the V1 Region of Simian Immunodeficiency Virus gp120 Results in Redirection of B-Cell Responses to V3. J. Virol.
78: 1525-1539
[Abstract]
[Full Text]
-
Johnson, W. E., Sanford, H., Schwall, L., Burton, D. R., Parren, P. W. H. I., Robinson, J. E., Desrosiers, R. C.
(2003). Assorted Mutations in the Envelope Gene of Simian Immunodeficiency Virus Lead to Loss of Neutralization Resistance against Antibodies Representing a Broad Spectrum of Specificities. J. Virol.
77: 9993-10003
[Abstract]
[Full Text]
-
Johnson, W. E., Lifson, J. D., Lang, S. M., Johnson, R. P., Desrosiers, R. C.
(2002). Importance of B-Cell Responses for Immunological Control of Variant Strains of Simian Immunodeficiency Virus. J. Virol.
77: 375-381
[Abstract]
[Full Text]
-
Quinones-Kochs, M. I., Buonocore, L., Rose, J. K.
(2002). Role of N-Linked Glycans in a Human Immunodeficiency Virus Envelope Glycoprotein: Effects on Protein Function and the Neutralizing Antibody Response. J. Virol.
76: 4199-4211
[Abstract]
[Full Text]
-
Johnson, W. E., Sauvron, J. M., Desrosiers, R. C.
(2001). Conserved, N-Linked Carbohydrates of Human Immunodeficiency Virus Type 1 gp41 Are Largely Dispensable for Viral Replication. J. Virol.
75: 11426-11436
[Abstract]
[Full Text]
-
Mori, K., Yasutomi, Y., Ohgimoto, S., Nakasone, T., Takamura, S., Shioda, T., Nagai, Y.
(2001). Quintuple Deglycosylation Mutant of Simian Immunodeficiency Virus SIVmac239 in Rhesus Macaques: Robust Primary Replication, Tightly Contained Chronic Infection, and Elicitation of Potent Immunity against the Parental Wild-Type Strain. J. Virol.
75: 4023-4028
[Abstract]
[Full Text]
-
Petry, H., Pekrun, K., Hunsmann, G., Jurkiewicz, E., Lüke, W.
(2000). Naturally Occurring V1-env Region Variants Mediate Simian Immunodeficiency Virus SIVmac Escape from High-Titer Neutralizing Antibodies Induced by a Protective Subunit Vaccine. J. Virol.
74: 11145-11152
[Abstract]
[Full Text]
-
Means, R. E., Desrosiers, R. C.
(2000). Resistance of Native, Oligomeric Envelope on Simian Immunodeficiency Virus to Digestion by Glycosidases. J. Virol.
74: 11181-11190
[Abstract]
[Full Text]
-
Murphy, C. G., Lucas, W. T., Means, R. E., Czajak, S., Hale, C. L., Lifson, J. D., Kaur, A., Johnson, R. P., Knipe, D. M., Desrosiers, R. C.
(2000). Vaccine Protection against Simian Immunodeficiency Virus by Recombinant Strains of Herpes Simplex Virus. J. Virol.
74: 7745-7754
[Abstract]
[Full Text]
-
Ly, A., Stamatatos, L.
(2000). V2 Loop Glycosylation of the Human Immunodeficiency Virus Type 1 SF162 Envelope Facilitates Interaction of This Protein with CD4 and CCR5 Receptors and Protects the Virus from Neutralization by Anti-V3 Loop and Anti-CD4 Binding Site Antibodies. J. Virol.
74: 6769-6776
[Abstract]
[Full Text]
-
Auerbach, M. R., Czajak, S. C., Johnson, W. E., Desrosiers, R. C., Alexander, L.
(2000). Species Specificity of Macaque Rhadinovirus Glycoprotein B Sequences. J. Virol.
74: 584-590
[Abstract]
[Full Text]